Suppr超能文献

用前列腺癌异抗原免疫可引起异抗原表位特异性 T 细胞反应。

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.

机构信息

Department of Medicine; University of Wisconsin; Madison, WI USA.

出版信息

Oncoimmunology. 2012 Dec 1;1(9):1546-1556. doi: 10.4161/onci.22564.

Abstract

Vaccines encoding xenoantigens, "non-self" proteins that are highly homologous to their autologous counterparts, have been investigated as a means to increase immunogenicity and overcome tolerance to "self" antigens. We have previously shown that DNA vaccines encoding native prostatic acid phosphatase (PAP) were able to elicit PAP-specific T cells in both rats and humans, but required multiple immunization courses. In this study, we investigated in a preclinical model whether immunizations with a DNA vaccine encoding a xenoantigen could elicit a cross-reactive immune response to the native protein, potentially requiring fewer immunizations. Lewis rats were immunized with a DNA vaccine encoding human PAP and splenocytes from immunized rats were screened with a human peptide library containing overlapping, 15-mer PAP-derived peptides using T-cell proliferation and interferon γ (IFNγ) release as measures of the immune response. One dominant PAP-specific, RT1.A(l)-restricted, epitope was identified. Direct immunization with the immunodominant peptide (HP(201-215)) containing this epitope demonstrated that it included a naturally presented MHC Class I epitope recognized by CD8(+) T cells in Lewis rats. However, no cross-reactive immune response was elicited to the corresponding rat peptide despite a difference of only three amino acids. Immunization with DNA vaccines encoding rat PAP (rPAP) in which this foreign dominant epitope was included as well as with DNA vaccines coding for a variant of the xenoantigen from which this epitope was deleted, did not elicit responses to the native antigen. Overall, these results indicate that the immunization with a xenoantigen-coding DNA vaccine can lead to an immune response which potentially favors foreign epitopes and hence limits any cross-reactive response to the native antigen.

摘要

疫苗编码异种抗原,即与自身蛋白高度同源的“非自身”蛋白,已被研究用于提高免疫原性并克服对“自身”抗原的耐受。我们之前已经表明,编码天然前列腺酸性磷酸酶(PAP)的 DNA 疫苗能够在大鼠和人类中引发 PAP 特异性 T 细胞,但需要多次免疫接种。在这项研究中,我们在临床前模型中研究了用编码异种抗原的 DNA 疫苗免疫是否能引发对天然蛋白的交叉反应性免疫应答,从而可能需要较少的免疫接种次数。Lewis 大鼠用编码人 PAP 的 DNA 疫苗免疫,用含有重叠 15 肽的人肽文库筛选免疫大鼠的脾细胞,以 T 细胞增殖和干扰素γ(IFNγ)释放作为免疫应答的衡量标准。鉴定出一个主要的 PAP 特异性、RT1.A(l)-限制性表位。用包含该表位的免疫显性肽(HP(201-215))直接免疫,表明它包含一个由 Lewis 大鼠 CD8+T 细胞识别的天然呈递 MHC Ⅰ类表位。然而,尽管只有三个氨基酸的差异,针对相应的大鼠肽却没有引发交叉反应性免疫应答。用包含该外来显性表位的编码大鼠 PAP(rPAP)的 DNA 疫苗以及用删除该表位的编码该异种抗原的变体的 DNA 疫苗免疫,均不能引发对天然抗原的反应。总的来说,这些结果表明,用编码异种抗原的 DNA 疫苗免疫可以引发一种免疫应答,这种应答可能有利于外来表位,从而限制对天然抗原的任何交叉反应性应答。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5393/3525610/8d98e68a3b5f/onci-1-1546-g1.jpg

相似文献

2
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Cancer Immunol Immunother. 2007 Jun;56(6):885-95. doi: 10.1007/s00262-006-0241-8. Epub 2006 Nov 11.
3
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.
5
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Vaccine. 2006 Jan 16;24(3):293-303. doi: 10.1016/j.vaccine.2005.07.074. Epub 2005 Aug 9.
7
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.
8
Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
Mol Immunol. 2007 Apr;44(11):3037-48. doi: 10.1016/j.molimm.2007.01.001. Epub 2007 Feb 15.
10
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
J Immunol. 2001 Dec 15;167(12):7150-6. doi: 10.4049/jimmunol.167.12.7150.

引用本文的文献

1
β-amino acid substitution in the SIINFEKL antigen alters immunological recognition.
Cancer Biol Ther. 2025 Dec;26(1):2486141. doi: 10.1080/15384047.2025.2486141. Epub 2025 Apr 8.
2
DNA vaccines for prostate cancer.
Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Epub 2017 Feb 7.
3
DNA vaccination for prostate cancer: key concepts and considerations.
Cancer Nanotechnol. 2015;6(1):2. doi: 10.1186/s12645-015-0010-5. Epub 2015 Jul 2.
6
DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. Epub 2014 Jan 31.
7
Preclinical and clinical development of DNA vaccines for prostate cancer.
Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12.
8
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.
Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.
9
Trial Watch: Anticancer radioimmunotherapy.
Oncoimmunology. 2013 Sep 1;2(9):e25595. doi: 10.4161/onci.25595. Epub 2013 Jul 3.

本文引用的文献

1
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.
2
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.
3
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
4
Structural and functional analysis of human prostatic acid phosphatase.
Expert Rev Anticancer Ther. 2010 Jul;10(7):1055-68. doi: 10.1586/era.10.46.
6
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.
7
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.
9
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
Mol Ther. 2007 Nov;15(11):2044-50. doi: 10.1038/sj.mt.6300290. Epub 2007 Aug 28.
10
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Cancer Immunol Immunother. 2007 Jun;56(6):885-95. doi: 10.1007/s00262-006-0241-8. Epub 2006 Nov 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验